Goldman Sachs raised the firm’s price target on Kestra Medical (KMTS) to $25 from $22 and keeps a Neutral rating on the shares. The company’s Q2 revenue of $22.6 million came in line with the preliminary guidance update in early December and reflected 53% y/y growth, with the performance in the quarter driven by 54% y/y growth in prescriptions, the analyst tells investors in a research note. Gross margins came in at 50.6% for Q2 and compared to 39.6% in the prior year period and was driven by volume leverage and improving revenue conversion, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical Technologies Reports Strong Earnings Growth
- Kestra Medical price target raised to $30 from $28 at Stifel
- Morning Movers: Cannabis stocks higher after reports of reclassification
- Kestra Medical price target raised to $28 from $27 at Wells Fargo
- Kestra Medical price target raised to $30 from $27 at Piper Sandler